[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ultrasound-therapy-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ultrasound-therapy-complications":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,71,103,126,153,181,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100589500","effect-of-alcohol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-women-with-ovarian-endometriosis-100589500",false,"NCT06955221","Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis","Effect of US-guided Alcohol Sclerotherapy for Endometriomas on Pelvic Pain and Quality of Life","ESCOMA","Inclusion Criteria:\n\n* Female sex\n* Age ≥18 and ≤45 years\n* Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm\n* Size between 30-100 mm, persistent for at least 3-6 months since diagnosis\n* Ca125 marker \\\u003C300 UI\u002FmL and HE4 \\\u003C 70 pM\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* History of ovarian or uterine cancer\n* Endometrioma size \\\u003C30 mm or \\>100 mm\n* Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause\n* Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy\n* Ca125 \\>300 UI\u002FmL\n* HE4 \\>70 pM\n* Pregnant women\n* Patients who do not wish to participate in the study or who are mentally incapacitated","FEMALE","18 Years","45 Years",{"count":21,"type":22},288,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management.\n\nThe main questions it aims to answer are:\n\n1. \\- Does sclerotherapy significantly reduce pelvic pain compared to expectant management?\n2. \\- Does sclerotherapy improve quality of life as measured by the EHP-5 score?\n\nResearchers will compare the sclerotherapy group to the expectant management group to determine whether the intervention leads to greater improvement in pain and quality of life.\n\nParticipants will:\n\n* Be randomly assigned to one of two groups: (1) Sclerotherapy group: undergo ultrasound-guided puncture and alcohol sclerotherapy; (2) Control group: expectant management\n* Complete quality of life and pain assessments at baseline and after 6 months\n* Provide blood and urine samples for biomarker analysis (e.g., cortisol, IL-6, hsCRP, catecholamines)\n* Undergo ovarian reserve assessments (AMH, antral follicle count)\n* Be followed for adverse events, recurrence, fertility outcomes, and treatment-related costs\n\nThe study will follow an intention-to-treat and per-protocol analysis approach.",[28,29,30,31],"Endometrioma","Ultrasound Therapy; Complications","Quality of Life","Pelvic Pain","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2025-01-01",{"date":40,"type":22},"2027-12-31",{"name":42,"class":43},"Hospital Universitari de Bellvitge","OTHER",28,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100498381","prediction-of-germline-brca-12-genes-from-healthy-ovaries-100498381","NCT05769517","Prediction of Germline BRCA 1\u002F2 Genes From Healthy Ovaries","Prediction of Germline BRCA 1\u002F2 Genes Pathogenetic Variants From Healthy Ovaries Ultrasound Images: Radiogenomics as an Innovative Tool to Prevent BRCA-related Cancers","PROBE-II","Inclusion Criteria:\n\nAvailability of gBRCA1\u002F2 test results\n\nTransvaginal pelvic US performed providing at least one picture of one healthy ovary\n\nUS images stored in .dicom format.\n\nExclusion Criteria:\n\nPersonal diagnosis of OC\n\nOvarian abnormal findings (eg. ovarian endometriomas, dermoid cyst, ovarian cystoadenofibroma, ovarian borderline tumour…) with the exception of functional cysts at pelvic US\n\ngBRCA1\u002F2 testing results nor provided by an ISO 1589 accredited laboratory\n\nRefusal to provide written informed consent",true,{"count":55,"type":22},6465,"OBSERVATIONAL","The project aims at enhancing performance metrics and prospectively validating a radiogenomics model based on ovarian US images for predicting germline breast cancer susceptibility gene 1 and\u002For 2 (BRCA) status in women with healthy ovaries. The project is divided in two operational phases:\n\nModel development phase (ambispective)\n\nAIM 1: To define and implement a proper and fine-tuned image preprocessing pipeline on the existing dataset; AIM 2: To enlarge dataset size with new real images from different centers and apply data augmentation techniques, deep neural network models combined with the aforementioned handcrafted imaging features from radiomics analysis;\n\nImplementation and validation phase (prospective)\n\nAIM 3: To further cross-validate the predictive model on US images acquired prospectively in an observational multicenter study.",[59,60,29],"BRCA Mutation","Ovarian Cancer","2026-04-21",{"date":63,"type":36},"2026-04-24",{"date":65,"type":36},"2023-03-20",{"date":67,"type":22},"2031-03-08",{"name":69,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100552711","phase-3-a-phase-iii-randomised-clinical-trial-of-ultrasound-groin-monitoring-versus-groin-lymph-node-dissection-to-de-escalate-the-extent-of-surgery-in-vulvar-cancer-100552711","NCT06476639","A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer","ANVU","Inclusion Criteria:\n\n* Females, over 18 years, with histologically confirmed SCC or adenocarcinoma of the vulva\n* Clinically stage 1b or 2 on medical imaging (CT or MRI scan of pelvis, abdomen, and chest), without evidence of regional or distant metastatic disease\n* Willing and able to undergo IFL\u002FSNB according to local clinical practice management guidelines\n* Willing and able to comply with all study requirements, timing and\u002For nature of required assessments.\n* Signed written informed consent\n* Negative (serum or urine) pregnancy (BHCG) test ≤ 30 days of surgery ONLY in pre-menopausal women and women \\\u003C 2 years after the onset of menopause.\n\nExclusion Criteria:\n\n* Women with non-invasive vulvar conditions (e.g. non-invasive non-mammary Paget's disease)\n* Clinical or medical imaging evidence of regional and\u002For distant metastatic disease\n* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)\n* Other prior malignancies \\\u003C5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ\n* Estimated life expectancy of ≤6 months",{"count":79,"type":22},640,[81],"PHASE3","This study is a phase III, open label, multicentre, three-group, randomised clinical trial. The primary aim of this study is to determine whether intensive groin ultrasound monitoring (1) is effective and safe to replace invasive groin lymph node dissection (LND) to manage vulvar cancer, (2) decreases the morbidity associated with vulvar cancer surgery, and (3) is cost effective.",[84,85,86,87,29],"Vulvar Cancer Stage I","Vulvar Cancer Stage II","Lymph Node Metastasis","Groin Node",[89,90],"Vulvar Cancer","Ultrasound Therapy","NOT_YET_RECRUITING","2026-03-19",{"date":94,"type":36},"2026-03-24",{"date":96,"type":22},"2026-06-01",{"date":98,"type":22},"2035-12-31",{"name":100,"class":101},"Queensland Centre for Gynaecological Cancer","OTHER_GOV",9,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":125},"100536387","node-groin-ultrasound-cancer-100536387","NCT06264167","NODE (groiN ultrasOunD cancEr)","Randomised Feasibility Study of Groin Ultrasound Surveillance to De-Escalate Surgical Intervention in Women With Vulvar Cancer","NODE","Inclusion Criteria:\n\n* Women, over 18 years, with histologically confirmed SCC or adenocarcinoma of the vulva\n* Clinically stage I or II on medical imaging (CT scan of pelvis, abdomen, and chest), without evidence of regional or distant metastatic disease\n* Participant must be suitable to undergo IFL\u002FSNB according to local clinical practice management guidelines\n* Signed written informed consent\n* Negative serum pregnancy test ≤ 30 days of surgery in pre-menopausal women and women \\\u003C 2 years after the onset of menopause\n* Patient lives within 40 km of a medical diagnostic imaging centre (site investigator approval required for special circumstances)\n\nExclusion Criteria:\n\n* Women with non-invasive vulvar conditions (e.g. non-invasive non-mammary Paget's disease)\n* Clinical or medical imaging evidence of regional and\u002For distant metastatic disease\n* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)\n* Other prior malignancies \\\u003C5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ\n* Estimated life expectancy of ≤6 months",{"count":112,"type":22},30,[25],"This study is an open label, prospective, experimental, randomised clinical trial. The primary aim of this study is to determine whether it is feasible to randomise vulvar cancer patients into one of two treatment arms:1) surgical groin node dissection (as delivered though either a sentinel node biopsy or inguinofemoral lymph node dissection (IFL), or 2) serial high-resolution bilateral groin ultrasound surveillance and clinical examination every 2 months for 12 months.",[116,85,86,87,29],"Vulvar Cancer Stage Ib",[89,90],"2026-02-18",{"date":120,"type":36},"2026-02-20",{"date":122,"type":36},"2024-07-01",{"date":40,"type":22},{"name":100,"class":101},5,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":133,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100509500","non-invasive-ultrasound-retinal-stimulation-for-vision-restoration-100509500","NCT05914233","Non-invasive Ultrasound Retinal Stimulation for Vision Restoration","Revolutionary Non-Invasive Ultrasound Technology for Vision Restoration in Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) Patients","Inclusion Criteria:\n\n1. Diagnosis of AMD (regardless of stage and type) or RP. At least two volunteers should diagnose with RP.\n2. Age 18 years or older\n3. No other eye-related health conditions\n4. No allergic history to commercial ultrasound gel\n5. Must be willing and able to comply with the protocol testing\n\nExclusion Criteria:\n\n1. Declining to participate and inability to give informed consent.\n2. Unable to comply with the process of the research\n3. If the volunteer has optic nerve disease, including the history of glaucoma, optic neuropathy, or other confirmed damage to optic nerve or visual cortex damage\n4. Unable to fixate that hinders obtaining high-quality imaging\n5. High myopia; refractive error of six diopters and above\n6. Pregnancy\n7. Subject is participating in another investigational drug or device study that may conflict with the objectives, follow-up, or testing of this study","ALL",{"count":125,"type":22},[25],"This clinical trial aims to test the safety and feasibility of using a non-invasive ultrasound device to stimulate retinal nerve cells and restore vision in patients with age-related macular degeneration. Previous studies have shown that artificial stimulation, such as electric and optic stimulations, can partially restore vision, but these methods are invasive and pose surgical risks. The study aims to develop a non-invasive method for retinal stimulation. The investigators will follow the FDA guidelines to limit the ultrasound power and adhere to all clinical trial regulations to ensure all participants' safety.\n\nThe main questions the investigators aim to answer are:\n\n* Is using high-frequency ultrasound safe using a wearable device for localized retinal neural activity stimulation?\n* Does the stimulation through the device restore vision in patients with age-related macular degeneration?\n\nParticipants in this study will be asked to undergo Optical Coherence Tomography (OCT) scanning before and after the ultrasound stimulation to evaluate the device's safety. Then, they will receive five stimulation-rest cycles and complete a questionnaire to report what they see and how they feel during the device's operation.",[138,139,29],"Age-Related Macular Degeneration","Retinitis Pigmentosa",[141,142,143,138],"Ultrasound Stimulation","Retinal","Retinitis pigmentosa","2026-01-06",{"date":146,"type":36},"2026-01-08",{"date":148,"type":22},"2027-01-10",{"date":150,"type":22},"2028-07-15",{"name":152,"class":43},"University of Southern California",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":133,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":70},"100577026","investigation-of-the-effect-of-using-curtain-100577026","NCT06792942","Investigation of the Effect of Using \"Curtain\"","Investigation of the Effect of Using \"Curtain\" as a Distraction Method on Fear, Anxiety and Pain in Diagnostic Procedures Performed in Patients With Suspected Thyroid Mass","Inclusion Criteria:\n\n* Suspicion of a mass in the thyroid\n* No vision problems\n\nExclusion Criteria:\n\n* Mental health problems","75 Years",{"count":162,"type":22},100,[25],"Thyroid nodules are among the common health problems in adulthood. Thyroid cancers account for approximately 1% of all malignancies in a year.The majority of cancers are diagnosed by thyroid fine needle aspiration biopsy. The most commonly diagnosed cancer type is papillary thyroid cancer and accounts for 85% of all thyroid cancers.Thyroid Ultrasonography is the most important imaging method used in the evaluation of the thyroid gland and its nodules. It enables the detection of nodules and their characteristics and plays a role in deciding which nodules should be evaluated with fine needle aspiration biopsy.Non-pharmacological treatment methods are interventions that can be used to reduce the side effects of medical, surgical or pharmacological treatments. By using medical treatment and complementary therapy together, nurses can reduce patients' anxiety, support their sleep, create a healing environment and increase their health level.\n\nAs a non-pharmacological strategy, distraction can be seen as a cost-effective approach to reduce anxiety in procedures that would cause negative anxiety and increase the opportunity for ease of operation. The curtain method also typically involves the use of visually interesting curtains or partitions that can be drawn around the patient's examination area. These curtains may have calming images or vibrant patterns that can help shift the patient's focus away from the frightening procedure being performed.",[29,166,167],"Fine Needle Aspiration Biopsy","Thyroid Nodule (Diagnosis)",[169,29,170,171],"The curtain","Ultrasound","Thyroid Nodule","2025-01-24",{"date":174,"type":36},"2025-01-27",{"date":176,"type":22},"2025-03-01",{"date":178,"type":22},"2025-09-30",{"name":180,"class":43},"Dicle University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":188,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100564846","spirometry-diaphragmatic-ultrasound-and-skeletal-muscle-mass-in-patients-with-chronic-obstructive-pulmonary-disease-100564846","NCT06634485","Spirometry ,diaphragmatic Ultrasound and Skeletal Muscle Mass in Patients with Chronic Obstructive Pulmonary Disease","Correlation Between Spirometry ,diaphragmatic Ultrasound and Skeletal Muscle Mass in Patients with Chronic Obstructive Pulmonary Disease : Case Control Study","Inclusion Criteria:\n\n* Group A (control group):\n\n  * This group include healthy volunteers who aged ≥ 40 years .\n* Group B (study group):\n\n  * This include stable COPD Patients who will be diagnosed by GOLD 2024 and last excerbation ≥ 6weeks .\n\nExclusion Criteria:\n\n* Group A (control group):\n\n  * Patients with disorders that may affect diaphragmatic function as\n\n    1. Musculoskeletal \u002F neurological disorders\n    2. diaphragmatic eventration \\\\ hiatus hernia\n    3. morbid obesity\n    4. recent thoracic\u002Fabdominal surgeries\n    5. pregnancy; pleurodesis \\\\fibrothorax.\n* Group B (study group):-\n\n  * Patients need for non- invasive ventilation.\n  * Patients with disorders that may affect diaphragmatic function as\n\n    1. Musculoskeletal \u002F neurological disorders\n    2. diaphragmatic eventration \\\\ hiatus hernia\n    3. morbid obesity\n    4. recent thoracic\u002Fabdominal surgeries\n    5. pregnancy; pleurodesis \\\\fibrothorax","MALE","41 Years","70 Years",{"count":192,"type":22},64,"* The primary objective is to evaluate the use of diaphragmatic function and skeletal muscle mass by ultrasound as a tool to establish the diagnosis of COPD and assess the severity of the disease.\n* The secondary objective is to compare diaphragmatic function, Skeletal muscle mass, and spirometry results in patients with COPD.",[195,29],"COPD",[195,197,198,199],"Diaphragmatic Ultrasound","Spirometry","Skeletal Muscle Mass","2024-10-08",{"date":202,"type":36},"2024-10-10",{"date":202,"type":22},{"date":205,"type":22},"2026-12-20",{"name":207,"class":43},"Assiut University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":53,"sex":133,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":70},"100441708","vision-based-ultrasonic-robot-autonomous-scanning-research-100441708","NCT05031884","Vision-based Ultrasonic Robot Autonomous Scanning Research","Inclusion Criteria:\n\n* patients who agree using MGIR3 to do ultrasonic examinations\n* age from 18 to 65\n\nExclusion Criteria:\n\n* Patients who has trauma on the inspection site or on the body surface\n* Pregnant patients.\n* Patients who are afraid of MGIR3-US","65 Years",{"count":216,"type":22},800,"MGIR3-US is a remote scanning robot which can perform ultrasound exam. The aim of the study is to evaluate the feasibility and the application of MGIR3-US.",[29],"2021-09-01",{"date":221,"type":36},"2021-09-02",{"date":223,"type":22},"2021-08-31",{"date":225,"type":22},"2026-08-31",{"name":227,"class":43},"Rongqin Zheng"]